-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by a alternating period of remission and recurrence
.
The researchers compared outcomes
for patients who met or did not meet the primary endpoint of the TAILORIX trial (defined as continuous corticosteroid-free clinical remission from weeks 22 to 54 and no ulcers on return colonoscopy at week 54).
A total of 95 patients (median duration 4.
This study confirmed that in this cohort of 95 patients with early-stage CD, steroid use for sustained clinical response and endoscopic complete remission was not associated with a reduction in disease progression
.
Original Source:
David Laharie.